Iris recognition makes no difference to wavefront-guided LASIK outcomes

Article

There are no statistically significant differences in outcomes when wavefront-guided LASIK is performed with or without iris recognition (IR), according to a report published in the September 2008 issue of the Journal of Cataract and Refractive Surgery.

There are no statistically significant differences in outcomes when wavefront-guided LASIK is performed with or without iris recognition (IR), according to a report published in the September 2008 issue of the Journal of Cataract and Refractive Surgery.

Theeraptep Tantayakom and colleagues from the Shiley Eye Center, University of California San Diego, California, US conducted a retrospective analysis of 112 eyes of 64 patients who had undergone wavefront-guided LASIK using the VISX CustomVue S4 IR platform (AMO) for either myopia or myopic astigmatism. The safety, efficacy, predictability and need for enhancement at three-month follow-up were analyzed and compared between those in the IR group and those in the non-IR group.

At three-months follow-up, 93% of eyes in the non-IR group and all eyes in the IR group had the same best spectacle-corrected visual acuity (BSCVA) as preoperatively or had gained one or two lines. No eye in either group lost more than one line (p=0.12). Furthermore, 96% of eyes in the IR group and 93% of eyes in the non-IR group were within ±0.50 D of the postoperative manifest refraction spherical equivalent (p=0.24) and all eyes were within ±1 D of emmetropia. Just four eyes in the IR group and 11 in the non-IR group required enhancements during the follow-up period (p=0.1).

It was the conclusion of Dr Tantayakom and co-workers that there are no differences in measured outcomes of wavefront-guided LASIK, whether IR is used or not.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.